Matrix Capital Management Company, LP 13D and 13G filings for Zentalis Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2023-06-20 4:30 pm Purchase |
2023-06-20 | 13D | Zentalis Pharmaceuticals, Inc. ZNTL |
Matrix Capital Management Company, LP | 13,959,973 19.810% |
4,760,000 (+51.74%) |
Filing |
| 2022-06-03 10:52 am Purchase |
2022-05-18 | 13D | Zentalis Pharmaceuticals, Inc. ZNTL |
Matrix Capital Management Company, LP | 9,199,973 16.450% |
4,850,694 (+111.53%) |
Filing |
| 2022-02-14 12:03 pm Purchase |
2021-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Matrix Capital Management Company, LP | 4,349,279 9.600% |
527,540 (+13.80%) |
Filing |
| 2021-02-16 10:02 am Purchase |
2020-12-31 | 13G | Zentalis Pharmaceuticals, Inc. ZNTL |
Matrix Capital Management Company, LP | 3,821,739 9.410% |
3,821,739 (New Position) |
Filing |